Jenburkt Pharmaceuticals reported a significant contraction in profitability for the first quarter of FY27, with standalone net profit after tax (PAT) falling 24.45% year-on-year to ₹588.56 lakhs. The decline comes against a backdrop of flat revenue growth and rising operational expenses, signaling pressure on margins despite stable top-line figures. Revenue from operations remained virtually unchanged at ₹3,551.20 lakhs, down slightly from ₹3,552.68 lakhs in Q1FY26.

The Board of Directors approved the unaudited financial results on August 6, 2026, following review by the Audit Committee. The results were prepared in accordance with Ind AS 34 and reviewed by statutory auditors D.R. Mehta & Associates under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review report confirmed no material misstatements in the disclosure.

Financial Performance

Revenue from operations stood at ₹3,551.20 lakhs, compared to ₹4,463.23 lakhs in the preceding quarter (Q4FY26) and ₹3,552.68 lakhs in Q1FY25. Total income, including other income of ₹151.32 lakhs, reached ₹3,702.52 lakhs. Other income declined sharply from ₹434.83 lakhs in Q4FY26, contributing to the overall income compression.

Earnings per share (EPS) for basic and diluted shares dropped to ₹13.34 from ₹17.66 in the same period last year. The company operates exclusively in the pharmaceuticals segment, rendering segment-wise reporting unnecessary.

What the Numbers Show

The primary driver behind the profit decline was a surge in employee benefit expenses, which rose to ₹1,302.52 lakhs in Q1FY27 from ₹1,172.08 lakhs in Q1FY26. This increase outpaced the negligible growth in revenue, squeezing operating margins. Additionally, other expenses climbed to ₹1,013.81 lakhs from ₹833.11 lakhs year-on-year. While cost of materials consumed decreased slightly to ₹231.59 lakhs, the overall expense burden increased relative to income generation. The absence of exceptional items in Q1FY27 contrasts with Q4FY26, where a one-time gain of ₹395.11 lakhs related to Labour Code impacts had boosted profits, though this is not directly comparable for sequential analysis.

Jenburkt Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for September 4, 2026, at 3:30 p.m. IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI-LODR). Shareholders holding shares as of the August 28, 2026 cut-off date are eligible to vote on all resolutions presented in the notice.

The company dispatched the notice convening the AGM, along with the Annual Report for the financial year 2025-26 (FY25-26), to members via electronic mode on August 3, 2026. This dispatch was made in accordance with Rule 20(4) of the Companies (Management and Administration) Rules, 2014, and Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025. Newspaper advertisements confirming the meeting were published in The Free Press Journal (English) and Navshakti (Marathi) on August 4, 2026.

E-Voting Schedule and Eligibility

Members can cast their votes using the remote e-voting facility provided by National Securities Depository Limited (NSDL). The voting window is open for three days prior to the AGM. Voting rights are proportional to the paid-up value of equity shares held as of the cut-off date.

Once a vote is cast via remote e-voting, it cannot be changed. Members who have already voted remotely may attend the AGM via VC/OAVM but cannot vote again. Those attending the meeting who have not voted remotely may exercise their voting rights during the AGM or within 15 minutes after its conclusion.

Regulatory Compliance and Member Instructions

The company complied with Regulation 36(1)(b) of SEBI-LODR by sending letters containing web-links to the complete Annual Report details to members who have not registered their email addresses with the company, Registrar to an Issue & Share Transfer Agent (RTA), or Depository Participants (DPs). The full notice and annual report are available on the company’s website at www.jenburkt.com and the BSE Limited website at www.bseindia.com .

Members are advised to update their PAN, contact details, bank account information, specimen signatures, and nomination details with their DPs if shares are held in demat form. Physical shareholders must submit duly filled Forms ISR-1 and ISR-2 to the company or RTA. Service requests can also be submitted online via the RTA’s ‘iConnect’ portal. For queries regarding login IDs or e-voting, members may contact NSDL’s Assistant Vice President, Veena Suvarna, or refer to the FAQs on www.evoting.nsdl.com .